PROVIDENCE-STRATEGIC
11.9.2020 10:01:09 CEST | Business Wire | Press release
Imaweb/ IDF Group, a leading independent provider of customer relationship management (“CRM”) solutions and dealership management systems (“DMS”) for the automotive industry in Europe, today announced that it has completed its acquisition of TMS-Soft, a leading provider of digital car registration workflow software in France. Imaweb/ IDF Group is backed by Providence Strategic Growth (“PSG”), the growth equity affiliate of premier asset management firm Providence Equity Partners (“Providence”). Financial terms were not disclosed.
Founded in 2008, TMS-Soft automates and streamlines processes associated with vehicle registration through its cutting-edge, digital platform. The company is the largest of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). TMS-Soft’s team serves over 3,700 clients ranging from used car dealerships, auto centers, and online car sales marketplaces.
Patrick Prajs, CEO of Imaweb/ IDF Group, said, “Our acquisition of TMS-Soft will enable us to offer clients a highly valuable add-on to their existing suite of Imaweb/IDF Group products, which are centered around our core CRM and DMS products. We will also be able to reach a broader base of customers – especially used-car dealerships – across all our markets. Today’s announcement is a testament of the momentum we have sustained since partnering with PSG, and we are optimistic about the road ahead. We are pleased to welcome the TMS-Soft team to our family and look forward to working together as we solidify our position as a leading European provider of CRM, DMS, and now digital workflow solutions for the automotive industry in Europe.”
Lionel Amrouche, Founder and CEO of TMS-Soft, said, “This transaction underscores the strength of the TMS-Soft brand and importance of our offering. We are excited for the future and look forward to growing the business under the Imaweb/ IDF Group umbrella.”
Since its formation following PSG’s investment in September 2019, Imaweb/ IDF Group has become one of Europe’s premier full-service providers of automotive CRM, DMS and other digital solutions. In the last 12 months, Imaweb/ IDF Group has also completed the acquisitions of ITMotive, a Netherlands-based distributor and servicer of DMS in the Benelux region, and Serinfer, the computer software segment of the Alvariño Group, a Spanish developer, distributor and supplier of DMS.
Imaweb/ IDF Group
Imaweb/ Datafirst-I’Car Systems Group (“Imaweb/ IDF Group”) is a leading developer of CRM and DMS solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems, a French software development company for car manufacturers, groups distribution and dealers, in 2019.
TMS-Soft
TMS-Soft is one of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). Through its digital platform, TMS-Soft facilitates all formalities associated with the registration process, with a focus on used vehicle registration. TMS-Soft was founded in 2008 by Lionel Amrouche, who continues to lead the business, and is powered by a team serving over 3,700 clients. Please visit https://www.tms-soft.fr/ for more information.
Providence Strategic Growth
PSG is an affiliate of Providence Equity Partners (“Providence”). Established in 2014, PSG focuses on growth equity investments in lower middle market software and technology-enabled service companies. Providence is a premier global asset management firm that pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 200 companies and is a leading equity investment firm focused on the media, communications, education, software and services industries. PSG is headquartered in Boston, MA, with offices in London and Kansas City. For more information on PSG, please visit https://www.provequity.com/private-equity/psg , and for more information on Providence, please visit https://www.provequity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom